Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis

被引:53
|
作者
Cutolo, Maurizio [1 ]
Ruaro, Barbara [1 ,2 ]
Pizzorni, Carmen [1 ,2 ]
Ravera, Francesca [1 ,2 ]
Smith, Vanessa [3 ]
Zampogna, Giuseppe [1 ,2 ]
Paolino, Sabrina [1 ,2 ]
Seriolo, Bruno [1 ,2 ]
Cimmino, Marco [1 ,2 ]
Sulli, Alberto [1 ,2 ]
机构
[1] Univ Genoa, Res Lab, I-16132 Genoa, Italy
[2] Univ Genoa, Acad Div Clin Rheumatol, Dept Internal Med, I-16132 Genoa, Italy
[3] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium
关键词
SYSTEMIC SCLEROSIS; RAYNAUD PHENOMENON; LASER DOPPLER FLOWMETRY; NAILFOLD VIDEOCAPILLAROSCOPY; ENDOTHELIN-1; ANTAGONIST; ILOPROST; RAYNAUDS-PHENOMENON; NAILFOLD VIDEOCAPILLAROSCOPY; CAPILLAROSCOPIC ANALYSIS; MICROVASCULAR CHANGES; DISEASE; MANAGEMENT; SEVERITY; DAMAGE;
D O I
10.3899/jrheum.131284
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To evaluate the longterm effects of endothelin-1 (ET-1) antagonism on peripheral blood perfusion (PBP) in patients with systemic sclerosis (SSc). Methods. Twenty-six patients with SSc already receiving cyclic intravenous iloprost (ILO) for severe Raynaud phenomenon were enrolled. Thirteen patients continued the treatment for a further 3 years (ILO group) and 13 patients, because of the appearance of digital ulcers, received in addition bosentan (BOS; 125 mg twice/day) for 3 years (ILO + BOS group). Both PBP at fingertips and nailfold microangiopathy were evaluated yearly by laser Doppler flowmetry and nailfold videocapillaroscopy, respectively. Results. A progressive significant increase of PBP was observed in the ILO + BOS group during the 3 followup years (p = 0.0007, p = 0.0002, p = 0.01, respectively). In contrast, an insignificant progressive decrease of PBP was observed in the ILO group. Difference of perfusion between the PBP evaluations at basal temperature and at 36 degrees C (to test capillary dilation capacity), was found progressively decreased during the 3-year followup only in the ILO group (p = 0.05, p = 0.26, p = 0.09, respectively). A progressive increase of nailfold capillary number was observed only in the ILO + BOS group after 2 and 3 years of followup (p = 0.05). Conclusion. Longterm treatment of SSc patients with ET-1 antagonism, in combination with ILO, seems to increase fingertip blood perfusion, as well as both capillary dilation capacity and number.
引用
收藏
页码:881 / 886
页数:6
相关论文
共 50 条
  • [41] Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients
    Sulli, A.
    Ruaro, B.
    Alessandri, E.
    Pizzorni, C.
    Cimmino, M. A.
    Zampogna, G.
    Gallo, M.
    Cutolo, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 247 - 251
  • [42] Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study
    Nguyen, Van Anh
    Eisendle, Klaus
    Gruber, Ingrid
    Hugl, Beate
    Reider, Daniela
    Reider, Norbert
    RHEUMATOLOGY, 2010, 49 (03) : 583 - 587
  • [43] Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil
    Ambach, Andreas
    Seo, Won
    Bonnekoh, Bernd
    Gollnick, Harald
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (10): : 888 - 891
  • [44] Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
    Stern, Edward
    Host, Lauren
    Escott, K. Jane
    Gilmour, Peter
    Wanjiku, Ivy
    Ochiel, Rachel
    Burns, Aine
    Unwin, Robert
    Ong, Voon
    Denton, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [45] STELLATE BLOCKADE COMBINED TO ILOPROST AS SUPPORTIVE TREATMENT OPTION IMPROVES PAIN AND ISCHAEMIC SYMPTOMS IN PATIENTS WITH SYSTEMIC SCLEROSIS
    Hocketstaller, F.
    Henkemeier, U.
    Zimmermann, M.
    Burkhardt, H.
    Behrens, F.
    Drott, U.
    Koehm, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1104 - 1104
  • [46] Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron
    Stratz, T
    Müller, W
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2004, 33 : 59 - 62
  • [47] Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis
    Arefiev, Kait
    Fiorentino, David F.
    Chung, Lorinda
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011
  • [48] An endothelin receptor antagonist improves portal hypertension and hepatic blood flow in experimental cirrhotic rats.
    Ueno, T
    Tamaki, S
    Torimura, T
    Kusaba, N
    Sakamoto, M
    Ogata, R
    Kim, K
    Inuzuka, S
    Sata, M
    Tanikawa, K
    HEPATOLOGY, 1998, 28 (04) : 192A - 192A
  • [49] Effect of the endothelin receptor inhibitor (bosentan) on right ventricular myocardial performance index and aortic stiffness in patients with systemic sclerosis and pulmonary hypertension
    Moyssakis, I
    Gialafos, E
    Papadopoulos, D
    Vassiliou, V
    Votteas, V
    Sfikakis, R
    JOURNAL OF HYPERTENSION, 2005, 23 : S344 - S345
  • [50] A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis
    Chang, Sung Hae
    Jun, Jae Bum
    Lee, Yun Jong
    Kang, Tae Young
    Moon, Ki Won
    Ju, Ji Hyeon
    Kang, Seong Wook
    Choi, In Ah
    Park, Yong-Beom
    Lee, Seung Geun
    Lee, Shin-Seok
    Heo, Nam Hun
    Lee, Eun Bong
    RHEUMATOLOGY, 2021, 60 (12) : 5814 - 5819